Abstract
To evaluate the therapeutic efficacy and safety of neoadjuvant PD-1 inhibitor camrelizumab combined with TPF induction chemotherapy versus camrelizumab alone in patients with locally advanced resectable oral squamous cell carcinoma (OSCC). This study also aims to build predictive models for treatment decision based on a multivariable logistic regression analysis of multi-dimensional data.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
